Skip to main content

Table 4 Cost-effectiveness ratio

From: Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults

Treatment order

2-year expected cost (USD)

Expected period of the PL ≥ 30 × 109/L (years)

Cost-effectiveness ratio*

Difference between cost-effectiveness ratio

Sequence 1

40,980

1.75

23,438

ー

Sequence 2

39,822

1.79

22,280

1,158†

Sequence 3

33,551

1.78

18,826

4,612‡

  1. PL: platelet.
  2. * Two-year expected cost (USD)/period of PL ≥30 × 109/L (years).
  3. †Differences in the cost-effectiveness ratios between sequences 1 and 2.
  4. ‡Differences in the cost-effectiveness ratios between sequences 1 and 3.
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us